Pharmaceutical company Karyopharm Therapeutics Inc. (Nasdaq:KPTI) revealed on Thursday that the US Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) action date for the New Drug Application (NDA) for selinexor for the treatment of relapsed refractory multiple myeloma.
The company stated the previous PDUFA date for for selinexor has been extended by three months from 6 April 2019 to 6 July 2019.
Currently under the US FDA's Priority Review, the NDA is seeking accelerated approval for selinexor in combination with dexamethasone for the treatment of patients with relapsed refractory multiple myeloma who have received at least three prior therapies and whose disease is refractory to at least one proteasome inhibitor (PI), one immunomodulatory agent (IMiD), and one anti-CD38 monoclonal antibody.
Following the US FDA's Oncologic Drugs Advisory Committee (ODAC) meeting to discuss the selinexor NDA ODAC meeting, the company has submitted additional, existing clinical information as an amendment to the NDA, which allowed the US FDA to extend the PDUFA action date by three months.
According to the company, Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumour suppressor proteins in the cell nucleus. This reinitiates and amplifies their tumour suppressor function and is believed to lead to the selective induction of apoptosis in cancer cells, while largely sparing normal cells.
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories